In the first long-term ... Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy ...
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
The PEACE-1 trial (NCT01957436) revealed that adding radiotherapy to standard of care (SOC) and abiraterone significantly ...
Half of ALS patients experience constipation, which is associated with faster progression and lower survival rates, per a ...
Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).
Riluzole treatment and a diet containing high glycemic index foods interact 'synergistically' to slow ALS progression, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback